Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Oculopharyngeal Muscular Dystrophy (OPMD) Drugs key manufacturers include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. Benitec Biopharma Inc., Bioblast Pharma, BioMarin are top 3 players and held % sales share in total in 2022.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs can be divided into Tablets, Capsules, Injectable and Other, etc. Tablets is the mainstream product in the market, accounting for % sales share globally in 2022.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry development. In 2022, global % sales of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Segment by Type
Tablets
Capsules
Injectable
Other
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oculopharyngeal Muscular Dystrophy (OPMD) Drugs introduction, etc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Hospital Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Oculopharyngeal Muscular Dystrophy (OPMD) Drugs key manufacturers include Benitec Biopharma Inc., Bioblast Pharma, BioMarin, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd, Santhera Pharmaceuticals, Pfizer Inc. and Marathon Pharmaceuticals, etc. Benitec Biopharma Inc., Bioblast Pharma, BioMarin are top 3 players and held % sales share in total in 2022.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs can be divided into Tablets, Capsules, Injectable and Other, etc. Tablets is the mainstream product in the market, accounting for % sales share globally in 2022.
Oculopharyngeal Muscular Dystrophy (OPMD) Drugs is widely used in various fields, such as Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, etc. Hospital Pharmacies provides greatest supports to the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry development. In 2022, global % sales of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs went into Hospital Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Benitec Biopharma Inc.
Bioblast Pharma
BioMarin
PTC Therapeutics
NS Pharma
Nobelpharma Co., Ltd
Santhera Pharmaceuticals
Pfizer Inc.
Marathon Pharmaceuticals
Fibrogen
Bristol-Myers Squibb
Sarepta Therapeutics
GSK
Segment by Type
Tablets
Capsules
Injectable
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Oculopharyngeal Muscular Dystrophy (OPMD) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Oculopharyngeal Muscular Dystrophy (OPMD) Drugs introduction, etc. Oculopharyngeal Muscular Dystrophy (OPMD) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Oculopharyngeal Muscular Dystrophy (OPMD) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices